MGI Pharma’s Salagen
Executive Summary
NDA submitted Feb. 24 for Minneapolis-based company's pilocarpine drug for the treatment of radiation-induced xerostomia (dry mouth) in head and neck cancer patients, an orphan indication. Salagen is the first prescription drug developed by MGI Pharma that has been sent to the agency for approval. The company is seeking a partner to market the product outside of North America.